Shuang Qiao

Chief Executive Officer at Vivace Therapeutics.

Raised on Vivace Therapeutics filings

$17.5M

of $35M offered across 1 Form D filing

Company

Biotech · San Mateo, CA

Hippo pathway drugs for mesothelioma and solid tumors

Hippo pathway drugs for mesothelioma and solid tumors

Vivace Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Mar 12, 2025	Equity	$17.5M/ $35M	Form D

Also named on Vivace Therapeutics filings